Hi everyone,
NICE recently announced that they will be conducting a Health Technology Appraisal (HTA) for the use of voclosporin with immunosuppressives for treating lupus nephritis - nice.org.uk/guidance/indeve...
Voclosporin is a new drug for the treatment of lupus nephritis. It is a calcineurin inhibitor (CNI) used as an immunosuppressant medication – this is the same family of drugs as ciclosporin and tacrolimus.
As a key stakeholder, LUPUS UK will be contributing to each stage of the HTA. This includes nominating up to two Expert Clinicians and up to two Expert Patients to participate in the Committee Meeting which will be on 2nd November 2022 (it is expected to be conducted on Zoom).
We are seeking volunteers to nominate as Expert Patients for the Committee Meeting. To be considered you must:
- Have a diagnosis of lupus nephritis
- Have personal experience of moderate or severe lupus nephritis
- Be aged 18+
- Be a resident of the UK
- Be available to join the Committee Meeting on 2nd November 2022 (it is expected to be conducted on Zoom)
- Be will comfortable discussing your personal experiences and answering questions about your disease and treatment during the public meeting
The role of Expert Patients is very important during appraisals of lupus treatments because it ensures the voice of people living with lupus are considered in this important decision. During a meeting primarily focussed on graphs and numbers, their role is to remind the committee of the people behind all the statistics.
If you would like to be considered for nomination please email paul@lupusuk.org.uk
